Recently we reported effect of CYP2B6 genotype and wide between patient variability in plasma efavirenz concentration among Tanzanian HIV patients receiving efavirenz based HAART with or without rifampicin based anti-TB therapy [12], [13]. This evidence concerns the gene CYP2B6 and tuberculosis.